medigraphic.com

2013, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2013; 80 (1)

Imatinib: farmacocinética

Cruz-Rico J, Garrido-Acosta O, Anguiano-Robledo L, Rodríguez-Wong U, Pérez-Cruz E, Sánchez-Navarrete J, Ruiz-Pérez NJ, Montes-Vera MR

Language: Spanish
References: 18
Page: 67-72
PDF size: 223.95 Kb.


ABSTRACT

We noted the conditions in which is still useful imatinib, medication that changed the natural history of chronic myeloid leukemia. We do see, epidemiology, different forms of clinical presentation, evolution without the latest treatments and pathophysiology of the condition. A review of the mechanism of action of imatinib as a tyrosine kinase inhibitor, as well as absorption, dose modifications of this, biotransformation, elimination, interactions and mechanisms of drug resistance is subsequently made. Key words: Chronic myeloid


REFERENCES

  1. Jemal A. Cancer Statistics 2010. CA Cancer J Clin 2010; 60: 277.

  2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, et al. (eds.). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.

  3. Aguayo A, García-Álvarez E, Cázarez-Ordóñez Y, et al. Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in México City. Clinical Leukemia 2008; 2: 261-6.

  4. Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, González-Llano O, et al. La leucemia granulocítica crónica se presenta a una edad más temprana a la reportada en otros países en los pacientes de un hospital de concentración en México. Rev Hematol 2008; 9(Supl. 2): S1-S134; S47.

  5. Vargas-Viveros P, Hurtado-Monroy R, Cervera E, Best C, Aguayo A, Candelaria M. The age of Mexican patients with chronic myeloid leukemia (CML) Ph+ is quite younger than the reported in USA and European series. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 4291. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 4291.

  6. Cortes JE, Talpaz M, O’Brian S, et al. Staging of chronic myeloid leukemia in the imatinib era. Cancer 2006; 106: 1306-15.

  7. Deininger M, Buchdunger E, Druker BJ. The development of Imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-53.

  8. Epstein FH, et al. The biology of chronic myeloid leukemia. NEJM 1999: 164-72.

  9. Yaoyu Chen, Cong Peng, Dongguang Li, Shaoguang Li. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell 2010; 1(2): 124-32.

  10. Helhmann R, et al. Ann Oncol 2004.

  11. O’Brien SG, et al. NCCN Guidelines Version 2.2012; Panel Members Chronic Myelogenous Leukemia: 1-75.

  12. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.

  13. Capdeville R, Buchdunger E, Zimmerman J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.

  14. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007; 83: 53-60.

  15. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879-94.

  16. Pye SM, Cortes JE, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111: 5505-8.

  17. Eechoute K, Sparreboom A, Burger H, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clinical Cancer Research 2011; 17: 406-15.

  18. Kogel CH, Schellens J. The Oncologist, Clinical Pharmacology: Concise Drug Reviews. Imatinib 2007; 12: 1390-94.




2020     |     www.medigraphic.com